V2R13 Inhibitors
Chemical inhibitors of V2R13 can disrupt its function through various means, targeting different aspects of its signaling pathway and cellular processes. Palmitoyl Dl-FCCP operates by uncoupling mitochondrial oxidative phosphorylation, which leads to a decrease in ATP production. As ATP is essential for various cellular functions, including the translocation and recycling of V2R13, its reduction directly impairs the protein's ability to reach the cell surface or be recycled, thereby inhibiting its function. Genistein, on the other hand, acts as a tyrosine kinase inhibitor, preventing the phosphorylation of proteins that are critical for the signaling mechanisms of V2R13. LY294002 and Wortmannin both serve as inhibitors of phosphoinositide 3-kinases (PI3K), a group of enzymes involved in cellular functions such as protein trafficking and signal transduction; their inhibition consequently disrupts these processes for V2R13.
Continuing with the theme of targeting signaling pathways, SB203580 and PD98059 are selective inhibitors of p38 MAP kinase and MEK, respectively. Both p38 MAP kinase and MEK are components of the MAPK signaling pathway, which may be implicated in V2R13's activation and function. By inhibiting these kinases, the downstream signaling that is necessary for V2R13 to exert its effects is compromised. Inhibition by U73122, which targets phospholipase C (PLC), prevents the production of secondary messengers like IP3 and diacylglycerol, again leading to the suppression of V2R13 signaling. Protein kinase C (PKC), another enzyme that can be involved in V2R13's signaling cascade, is inhibited by chemicals such as Go6983 and Bisindolylmaleimide I, preventing PKC-mediated phosphorylation events crucial for V2R13 activity. ML-7 and W-7 inhibit myosin light chain kinase (MLCK) and calmodulin-dependent processes, respectively, which could affect V2R13 signaling related to cytoskeletal rearrangements and calcium signaling. Lastly, KN-93, which inhibits Ca2+/calmodulin-dependent protein kinase II (CaMKII), disrupts the calcium-dependent regulation of V2R13, further contributing to the inhibition of its function.
Share
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can inhibit the phosphorylation of proteins within cell signaling pathways, potentially reducing the functional activity of V2R13 if it relies on tyrosine kinase activity for signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinases (PI3K), which are involved in many signaling pathways, including those that may regulate the activity or trafficking of V2R13. Inhibition of PI3K can decrease the signaling required for V2R13 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which may be part of the signaling cascade that V2R13 engages in upon ligand binding. Inhibition of p38 MAP kinase can impair the downstream signaling necessary for V2R13's functional response. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is upstream of ERK in the MAPK signaling pathway. If V2R13's function is mediated through the MAPK pathway, inhibiting MEK would suppress ERK activation and thus inhibit V2R13 function. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a protein kinase C (PKC) inhibitor. If V2R13 signaling requires PKC-mediated phosphorylation events, Go6983 would inhibit these phosphorylations, thereby inhibiting V2R13 function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 inhibits myosin light chain kinase (MLCK). If V2R13 signaling involves cytoskeletal rearrangements mediated by MLCK activity, its inhibition would impair V2R13's functional responses. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 inhibits calmodulin-dependent processes. Since many signaling pathways, including those potentially involving V2R13, require calmodulin for signal transduction, W-7 would inhibit these pathways and thus inhibit V2R13 function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a PKC inhibitor. By inhibiting PKC, it would prevent PKC-dependent phosphorylation events that could be crucial for V2R13 signaling, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, it can prevent signaling events required for V2R13 function, such as membrane trafficking or signal transduction, leading to functional inhibition. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII). If V2R13 requires CaMKII for its signaling or regulation, KN-93 would inhibit those processes, thus functionally inhibiting V2R13. | ||||||